• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SVP and Corporate Controller Holzbaur Lynette sold $353,080 worth of shares (26,448 units at $13.35) and acquired 46 shares, closing all direct ownership in the company (SEC Form 4)

    5/7/26 4:00:40 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGN alert in real time by email
    SEC FORM 4/ASEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Holzbaur Lynette

    (Last)(First)(Middle)
    C/O ORGANON & CO.
    30 HUDSON STREET, FLOOR 33

    (Street)
    JERSEY CITY NEW JERSEY 07302

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Organon & Co. [ OGN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    SVP and Corporate Controller
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/06/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    05/07/2026
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock05/06/2026J45.939A$026,448.366(1)D
    Common Stock05/06/2026S26,448.366D$13.34980(2)D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. This reflects the acquisition of 45.939 shares of common stock not previously required to be reported.
    2. This amendment updates the reporting of the 26,448.366 shares in Table I to reflect a sale (disposition) instead of a purchase.
    Remarks:
    /s/ Tarnetta V. Jones, as Attorney-in-Fact for Lynette Holzbaur05/07/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $OGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OGN

    DatePrice TargetRatingAnalyst
    4/28/2026$14.00Underweight → Neutral
    Piper Sandler
    12/9/2025$7.50Underweight
    Barclays
    10/27/2025$5.00Overweight → Underweight
    Piper Sandler
    5/2/2025Outperform → In-line
    Evercore ISI
    9/6/2024$18.00 → $20.00Neutral → Underweight
    JP Morgan
    11/3/2023$33.00 → $16.00Buy → Neutral
    Goldman
    9/21/2023$28.00Overweight
    Barclays
    3/16/2023$33.00Outperform
    Raymond James
    More analyst ratings

    $OGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sharp Shalini

    4 - Organon & Co. (0001821825) (Issuer)

    6/15/26 4:41:46 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sequeira Ramona

    4 - Organon & Co. (0001821825) (Issuer)

    6/15/26 4:40:45 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Patton Cynthia M

    4 - Organon & Co. (0001821825) (Issuer)

    6/15/26 4:39:46 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and Corporate Controller Holzbaur Lynette bought $353,080 worth of shares (26,448 units at $13.35), increasing direct ownership by 100% to 52,851 units (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/7/26 10:02:30 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chair Cox Carrie Smith bought $501,755 worth of shares (65,400 units at $7.67) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    11/13/25 4:05:10 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cox Carrie Smith bought $100,591 worth of shares (12,469 units at $8.07) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/15/25 4:09:09 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

    Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission ("SEC"). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will be disclosed in a Form 8-K filing to be filed on the same day as the Form 10-Q. During the pendency of the previously announced acquisition by Sun Pharmaceutical Industries Limited on April 26, 2026, Organon has suspended its quarterly e

    7/16/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

    New analysis of pooled Phase 3 data will evaluate efficacy and safety of VTAMA cream across age groups in pediatric and adult patients with atopic dermatitis (AD) Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating VTAMA cream in AD will be presented at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting, taking place July 22 – 25, 2026, in Minneapolis, Minnesota. The presentation includes a pooled post hoc analysis of data from the pivotal Phase 3 ADORING 1 and ADORING 2 clinical trials evaluating the efficacy and safety of VTAMA

    7/7/26 8:00:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

    The launch expands Organon’s biosimilars portfolio in Canada to eight products spanning five therapeutic areas Organon Canada and Shanghai Henlius Biotech, Inc. (2696.HK) today announced that BILDYOS® (denosumab injection) 60 mg/1 mL and TUZEMTY® (denosumab injection) 120 mg/1.7 mL, biosimilars to PROLIA and XGEVA, respectively, are now available in Canada for all indications of reference products. Used across several indications, denosumab products treat osteoporosis and bone events associated with cancer by helping to strengthen bones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623760250/en/ "The approvals represent a

    6/23/26 5:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    SEC Filings

    View All

    SEC Form DEFA14A filed by Organon & Co.

    DEFA14A - Organon & Co. (0001821825) (Filer)

    7/17/26 4:12:44 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Organon & Co.

    8-K - Organon & Co. (0001821825) (Filer)

    7/17/26 4:01:17 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFM14A filed by Organon & Co.

    DEFM14A - Organon & Co. (0001821825) (Filer)

    6/17/26 6:04:32 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Organon upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Organon from Underweight to Neutral and set a new price target of $14.00

    4/28/26 7:28:27 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Organon with a new price target

    Barclays initiated coverage of Organon with a rating of Underweight and set a new price target of $7.50

    12/9/25 8:51:54 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Organon from Overweight to Underweight and set a new price target of $5.00

    10/27/25 11:23:41 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Leadership Updates

    Live Leadership Updates

    View All

    Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

    Organon (NYSE:OGN) ("Organon" or "the company") today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director. These appointments follow the resignation of Kevin Ali as Chief Executive Officer and member of the Board in connection with the Audit Committee investigation described below. Mr. Ali has agreed that he will not be entitled to severance o

    10/27/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

    Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

    4/15/25 5:00:00 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

    Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel

    3/10/25 12:01:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Financials

    Live finance-specific insights

    View All

    Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

    Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission ("SEC"). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will be disclosed in a Form 8-K filing to be filed on the same day as the Form 10-Q. During the pendency of the previously announced acquisition by Sun Pharmaceutical Industries Limited on April 26, 2026, Organon has suspended its quarterly e

    7/16/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

    Organon (NYSE:OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasiv

    6/10/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Reports Results for the First Quarter Ended March 31, 2026

    First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") in an all-cash transaction (the "merger"). The merger is expected to close in early 2027, subject to customary closing conditions, inc

    4/30/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    2/13/24 5:12:22 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    2/5/24 3:47:19 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    1/25/24 12:23:52 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care